Your browser doesn't support javascript.
loading
Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival.
Hoi, David M; Junker, Sabryna; Junk, Lukas; Schwechel, Kristin; Fischel, Katharina; Podlesainski, David; Hawkins, Paige M E; van Geelen, Lasse; Kaschani, Farnusch; Leodolter, Julia; Morreale, Francesca Ester; Kleine, Stefan; Guha, Somraj; Rumpel, Klaus; Schmiedel, Volker M; Weinstabl, Harald; Meinhart, Anton; Payne, Richard J; Kaiser, Markus; Hartl, Markus; Boehmelt, Guido; Kazmaier, Uli; Kalscheuer, Rainer; Clausen, Tim.
Afiliação
  • Hoi DM; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria; Max Perutz Labs, Vienna BioCenter, 1030 Vienna, Austria; Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, 1030 Vienna, Austria; University of Vienna, Center f
  • Junker S; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria.
  • Junk L; Saarland University, Organic Chemistry I, 66123 Saarbrücken, Germany; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), 66123 Saarbrücken, Germany. Electronic address: lukas.junk@helmholtz-hips.de.
  • Schwechel K; Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Fischel K; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria.
  • Podlesainski D; University of Duisburg-Essen, Center of Medical Biotechnology, Faculty of Biology, 45141 Essen, Germany.
  • Hawkins PME; School of Chemistry, University of Sydney, Sydney, NSW 2006, Australia; Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, NSW 2006, Australia.
  • van Geelen L; Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Kaschani F; University of Duisburg-Essen, Center of Medical Biotechnology, Faculty of Biology, 45141 Essen, Germany.
  • Leodolter J; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria.
  • Morreale FE; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria.
  • Kleine S; University of Duisburg-Essen, Center of Medical Biotechnology, Faculty of Biology, 45141 Essen, Germany.
  • Guha S; Saarland University, Organic Chemistry I, 66123 Saarbrücken, Germany.
  • Rumpel K; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria.
  • Schmiedel VM; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria.
  • Weinstabl H; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria.
  • Meinhart A; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria.
  • Payne RJ; School of Chemistry, University of Sydney, Sydney, NSW 2006, Australia; Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, NSW 2006, Australia.
  • Kaiser M; University of Duisburg-Essen, Center of Medical Biotechnology, Faculty of Biology, 45141 Essen, Germany.
  • Hartl M; Max Perutz Labs, Vienna BioCenter, 1030 Vienna, Austria; University of Vienna, Center for Molecular Biology, Department for Biochemistry and Cell Biology, 1030 Vienna, Austria.
  • Boehmelt G; Boehringer Ingelheim RCV GmbH & Co KG, 1120 Vienna, Austria.
  • Kazmaier U; Saarland University, Organic Chemistry I, 66123 Saarbrücken, Germany; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), 66123 Saarbrücken, Germany.
  • Kalscheuer R; Institute of Pharmaceutical Biology and Biotechnology, Heinrich Heine University, 40225 Düsseldorf, Germany.
  • Clausen T; Research Institute of Molecular Pathology, Vienna BioCenter, 1030 Vienna, Austria; Medical University of Vienna, 1030 Vienna, Austria. Electronic address: tim.clausen@imp.ac.at.
Cell ; 186(10): 2176-2192.e22, 2023 05 11.
Article em En | MEDLINE | ID: mdl-37137307
ABSTRACT
The ClpC1ClpP1P2 protease is a core component of the proteostasis system in mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease, we characterized the mechanism of the antibiotics cyclomarin A and ecumicin. Quantitative proteomics revealed that the antibiotics cause massive proteome imbalances, including upregulation of two unannotated yet conserved stress response factors, ClpC2 and ClpC3. These proteins likely protect the Clp protease from excessive amounts of misfolded proteins or from cyclomarin A, which we show to mimic damaged proteins. To overcome the Clp security system, we developed a BacPROTAC that induces degradation of ClpC1 together with its ClpC2 caretaker. The dual Clp degrader, built from linked cyclomarin A heads, was highly efficient in killing pathogenic Mycobacterium tuberculosis, with >100-fold increased potency over the parent antibiotic. Together, our data reveal Clp scavenger proteins as important proteostasis safeguards and highlight the potential of BacPROTACs as future antibiotics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis / Antituberculosos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis / Antituberculosos Idioma: En Ano de publicação: 2023 Tipo de documento: Article